Plenary Sessions
Monday, 6 November 2017
8:45 - 10:45
Room: Clyde Auditorium (Armadillo)
There now is a wide consensus that health care products and services should be priced in relation to the additional value they produce.  While cost-effectiveness analysis explicitly assumes allocation of resources based on added societal value, practitioners and health care policymakers in European institutions now increasingly promote value-based health care (VBHC) as a more holistic, patient-centered understanding of value. Although VBHC seems well aligned with cost-effectiveness analysis, there are several fundamental differences. Where VBHC is embraced by health care practitioners and hospital administrators because of its focus on patient value over the entire care pathways instead of single interventions, it lacks an operational definition of value in relation to cost. Another difference is that outcomes in VBHC are disease-specific, which implies they cannot be used for societal resource allocation decisions. This plenary session will therefore introduce VBHC in more general terms from a clinical and hospital perspective, and then will specifically discuss the challenges and main differences with cost-effectiveness analysis from an industrial, health economics, and patient perspective.
Moderator: Maarten J. IJzerman, PhD bio
Professor & Vice-Dean, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Speaker: Peter Naredi bio
Professor of Surgery & Head, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and President, European CanCer Organization (ECCO), Brussels, Belgium
Speaker: Luke Slawomirski bio
Health Economist & Policy Analyst, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD), Paris, France
Speaker: Bettina Ryll, MD, PhD bio
Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
Speaker: Jason Arora, BMBCh, MPH bio
Director, Value-Based Healthcare, Medtronic, London, UK
Tuesday, 7 November 2017
10:15 - 12:00
Room: Clyde Auditorium (Armadillo)
Health technology assessment (HTA) processes vary across jurisdictions.  Some countries are early adopters and include a formal economic evaluation (Canada, United Kingdom, Australia, Sweden, The Netherlands), others have a less arduous approach without formal QALY-type assessment (France, Spain, Italy), and still others prefer to reference HTAs performed elsewhere (Romania, Bulgaria).  In addition, bodies such as EUnetHTA offer the potential to streamline processes by enabling information sharing and structured collaboration between jurisdictions.  However, how cost-effective are the HTA processes? What is the value for money of the HTA activities? Is there a “perfect HTA process” that can serve as the benchmark for other countries to adopt or adapt?  This plenary session will explore how HTA processes (or lack of HTA processes) might be compared and evaluated.  The speakers will present different perspectives on evaluating the value of HTA processes and a discussant will provide an economist’s view.
Moderator: Andrew Briggs, DPhil bio
William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK
Speaker: Susan Guthrie, PhD, MSci bio
Research Leader, Rand Europe, Cambridge, UK
Speaker: Nicola Allen, PhD bio
Senior Consultant, Global Pricing and Product Strategy, Precision Xtract, London, UK
Speaker: Zoe Garrett, MPhil, MRes bio
Senior Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), & Lead, JA3 Work Package 7, EUnetHTA, Manchester, UK
Wednesday, 8 November 2017
11:15 - 12:45
Room: Clyde Auditorium (Armadillo)
As the rate of medical innovation accelerates, competing demands from various stakeholders put unprecedented pressure on health systems to deliver high-value medical care. Most health systems claim to link coverage decisions to the value for money afforded by specific treatments, but their approaches to valuation differ. Many countries, such as the United Kingdom, have historically relied on traditional cost-effectiveness analysis using the cost-per-QALY metric to guide coverage decisions. Other countries like France and Germany never adopted the uncertain place of cost-utility analysis in the decision processes", relying instead on disease-specific metrics. The large majority of payers in the pluralistic US health care market deny explicit consideration of cost effectiveness in coverage decisions, and US law forbids its use as part of the Affordable Care Act. Instead, public and private payers in the United States increasingly push financial risk onto health care providers thereby, in a sense, decentralizing the assessment of value.  Health economists from the United Kingdom, the United States, and France will provide reflective views on how valuation of medical technologies has changed across time and will discuss the methodological, societal, and political forces that shaped their evolution. The speakers will also consider what the future holds for valuation in health.  
Moderator: Shelby D. Reed, PhD, RPh bio
Professor, Duke University, Durham, NC, USA
Speaker: Mandy Ryan, PhD, MSc bio
Director of the Health Economics Research Unit, Institute of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
Speaker: Charles E. Phelps, PhD bio
University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA
Speaker: Jérôme Wittwer, PhD bio
Professor, Economics, Bordeaux University, Bordeaux, France
Contact ISPOR @ | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.